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New and recurrent AAGAB mutations in
punctate palmoplantar keratoderma
DOI: 10.1111/bjd.12927
DEAR EDITOR, Punctate palmoplantar keratoderma type I (PPPK1;
also known as Buschke-Fischer-Brauer type; OMIM 148600) is
an autosomal dominant disorder of keratinization, character-
ized by multiple hyperkeratotic lesions on the palms and soles
that usually start in early adolescence but may also start later
in life.1 Lesions increase in size and number with advancing
age and may coalesce over pressure points to form larger pla-
ques. Recently, two consecutive studies identified the causative
gene for PPPK1 as AAGAB,2,3 located on chromosome 15q23,
a locus to which the causal gene for PPPK1 was previously
mapped.4 Subsequently, further mutations in AAGAB were
described in families from several countries worldwide.5–11 In
this study, we investigated five European families with a clini-
cal diagnosis of PPPK1. This work was conducted in accor-
dance with the principles of the Declaration of Helsinki. Blood
was obtained following written informed consent and DNA
extracted using standard protocols. Polymerase chain reaction
amplification and Sanger sequencing to screen all exons and
exon/intron boundaries of AAGAB was done as described
previously.3
The 31-year-old proband from family 1, a four-generation
family of Swiss origin (Fig. 1a), presented with small, horny
nails and hyperkeratosis of the palms and soles. Age of
onset was 7 years. Discrete punctate lesions were observed
along the lateral edge of the plantar surface, with more
extensive hyperkeratosis over the heels (Fig. 1b). Peeling
skin was observed in the interdigital webspaces of the feet.
The proband’s father displayed extensive hyperkeratotic
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Fig 1. Pedigree, clinical images and mutation analysis of family 1. (a)
Pedigree showing a four-generation history of punctate palmoplantar
keratoderma. The arrowhead indicates the proband. (b) Punctate
hyperkeratotic lesions (arrows) around the lateral edge of the foot and
heel on the proband. (c) Palms of the father of the proband showing
multiple hyperkeratotic lesions. (d) DNA sequence of codons 86–88
of AAGAB in an unaffected control sample. (e) The same region as in
(d) from the proband of family 1. The arrow indicates the
heterozygous C>T mutation at c.262 resulting in nonsense mutation
p.Gln88*.
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lesions on his palms (Fig. 1c). We identified a previously
unreported heterozygous nonsense mutation p.Gln88*;
c.262C>T (Fig. 1d,e) within the GTPase domain of the p34
protein (Fig. 2e). This mutation is neither present in the
Database of Single Nucleotide Polymorphisms (http://www.
ncbi.nlm.nih.gov/SNP/) nor in the Exome Variant Server
(http://evs.gs.washington.edu/EVS/). The resulting haploin-
sufficiency in this family is consistent with the increase in
cell proliferation seen in PPPK lesions, as reported previ-
ously.3
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Fig 2. Pedigrees, clinical images and histology of punctate palmoplantar keratoderma type 1 families 2–5. (a) Pedigrees of the families with the
relevant mutations indicated. Arrows denote the proband, and asterisks show individuals in whom AAGAB was sequenced. (b) The palm of the
proband of family 3 showing the presence of multiple hyperkeratotic lesions. (c) Haematoxylin and eosin staining of a punch biopsy from palmar
skin from the proband in family 3. This shows compact orthokeratosis with a defined central depression within the lesion. (d) The plantar surface of
the index case in family 4. Hyperkeratotic lesions coalesce at pressure points. (e) Organization of the protein domains in p34 encoded by AAGAB,
illustrating the location of all mutations reported to date. The p.Gln88* mutation highlighted in red is the novel mutation reported in this study.
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In family 2, a 72-year-old Scottish woman was one of four
family members over three generations with palmoplantar ke-
ratoderma (Fig. 2a). She presented with a 1-year history of
worsening hyperkeratosis affecting primarily her soles. Small
hyperkeratotic lesions were seen on her fingers but not on
her palms. Both her children were affected, with hyperkerato-
sis developing at a much younger age than in herself. Her
two brothers were similarly affected, and her deceased father
was reported to have been affected. A recurrent heterozygous
nonsense mutation, p.Trp47*; c.140G>A,3,5 within the N-
terminal domain of p34 (Fig. 2e), was identified in the
proband.
The other three families studied were apparently unrelated
Danish kindreds. The 44-year-old proband of family 3
(Fig. 2a) developed dry palmar skin in her childhood
progressing to punctate keratosis on the palms (Fig. 2b) and
subsequently the soles. Haematoxylin and eosin staining of a
biopsy from palmar skin (Fig. 2c) showed compact orthokera-
tosis with pronounced hyperkeratosis. A central dermal
depression characteristic for punctate palmoplantar keratoder-
ma was observed. A recurrent heterozygous nonsense muta-
tion Arg124*; c.370C>T2 was identified in the proband and
four other affected members of this four-generation kin-
dred (Fig. 2a). PPPK1 was reported in four generations of
family 4 (Fig. 2a). The proband, a 53-year-old Danish female
developed PPPK1 at 18–20 years of age. It gradually became
worse, especially at pressure points on the feet (Fig. 2d)
where punctate lesions coalesced. The palms and volar sides of
the fingers were affected to a lesser degree. The same
p.Arg124* mutation as in family 3 was identified in the pro-
band, her affected daughter, son and aunt but not in an unaf-
fected sister (Fig. 2a). In family 5, PPPK1 developed around
the age of 20 years and progressed thereafter in the 68-year-
old Danish proband. She presented with severe, very painful
punctate palmoplantar keratoderma on the pressure points of
her soles. Palms were also affected with multiple 3–5-mm
punctate keratosis. Heterozygous nonsense mutation
p.Arg124* was also identified in this individual. Three unaf-
fected members did not carry the mutation (Fig. 2a).
PPPK1, an autosomal dominant disorder characterized by
multiple hyperkeratotic lesions on the palms and soles, can
vary in severity from mild to severe, and can be painful and
socially debilitating. Recently, mutations have been described
in the AAGAB gene, which encodes the a- and c-adaptin bind-
ing protein p34, and has been proposed to have a role in skin
integrity.2 p34 has been functionally implicated in the intra-
cellular transport of clathrin-coated vesicles,3 and may affect
cell signalling via regulation of the expression of receptor
tyrosine kinases, which are turned over by clathrin- and AP2-
dependant mechanisms.3,5,12,13 Recently a mutation was
reported in AAGAB in a Jewish family of Dutch origin with
PPPK1 co-segregating with congenital dislocation of the hip.10
Whether this is a coincidence or if AAGAB has an as yet
unknown role in skeletal development is unclear.
This study has revealed one novel, p.Gln88*, and two
recurrent, p.Trp47* and p.Arg124*, mutations. This brings
the total to 27 distinct loss-of-function mutations reported in
AAGAB (Fig. 2e), providing further evidence for this being the
causative gene for PPPK1.
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Body mass index, waist circumference and
HOMA-IR correlate with the Psoriasis Area and
Severity Index in patients with psoriasis
receiving phototherapy
DOI: 10.1111/bjd.12914
DEAR EDITOR, An increased incidence of obesity in patients with
psoriasis has been documented in cross-sectional studies of
large healthcare databases and case–control studies.1–7 Obesity,
and in particular centripetal obesity, confers a risk of develop-
ing insulin resistance and type 2 diabetes, which in turn
increases the risk of cardiovascular disease. Since 1978 it has
been known that patients with psoriasis have higher rates of
type 2 diabetes and cardiovascular disease and it is likely that
this is driven by obesity and concomitant insulin resistance.
We undertook a study to establish the effect of body mass
index (BMI), abdominal obesity and insulin resistance on pso-
riasis severity and Framingham risk. Following ethical
approval, consecutive patients with psoriasis, aged ≥ 18 years,
were recruited prior to commencing phototherapy or photo-
chemotherapy (TL-01 or psoralen plus ultraviolet A) between
October 2008 and July 2011. Patients had a full physical
examination and the Psoriasis Area and Severity Index (PASI)
score was recorded. Height, weight and waist circumference
were measured for each patient. The BMI was calculated using
the formula: weight in kg/(height in m)2. Obesity was
defined as a BMI > 30, overweight as BMI 25–30 and lean as
a BMI < 25 according to the World Health Organization defi-
nition of obesity. Systolic blood pressure was measured using
a sphygmomanometer on the left brachial artery. Fasting
blood samples were taken for the measurement of insulin,
glucose and serum cholesterol. Insulin resistance was mea-
sured using the homeostasis model with the formula: insulin
9 glucose/225 (HOMA-IR, homeostatic model assessment–
insulin resistance). Framingham risk was calculated using
MedCalc (MedCalc Software, Ostend, Belgium). Results were
analysed using GraphPad Prism (GraphPad Software Inc., La
Jolla, CA, U.S.A.), using Student’s t-test, ANOVA and Pearson’s
rank correlation.
A total of 103 patients were recruited from the photothera-
py department [mean age 40 years (range 21–69); mean PASI
96 (range 3–228); 52 male and 51 female]. When
categorized according to their BMI into lean (BMI < 25 kg
m2), overweight (BMI 25–30 kg m2) and obese (BMI
> 30 kg m2), 30% of the patients due to commence photo-
therapy were obese. Obese patients had significantly more
severe psoriasis than the lean or overweight patients when cat-
egorized according to BMI (n = 96, P = 0002) or according
to waist circumference (n = 90, P = 003) (Fig. 1).
There was a significant correlation between BMI and PASI
in patients prior to phototherapy (n = 97, r = 033,
P = 0001) (Fig. 2). When factors such as alcohol, smoking
and stress were controlled for in a multiple regression analy-
sis, the relationship between BMI and PASI remained signifi-
cant (P = 00005). PASI was also associated with waist
circumference (n = 103, r = 034, P = 00009). Abdominal
obesity is associated with diabetes, which has an increased
prevalence in patients with psoriasis. PASI was associated with
fasting insulin (n = 85, r = 048, P = 0001) and insulin
resistance as measured using HOMA-IR (n = 64, r = 048,
P = 0001) in patients receiving phototherapy. Patients with a
diagnosis of diabetes were excluded from this analysis. There
was also a positive correlation between Framingham risk and
BMI using Pearson’s correlation (n = 89, r = 024, P = 002)
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Fig 1. Obese patients prior to phototherapy
had significantly more severe psoriasis than
lean patients when compared using (a) body
mass index (BMI) (P = 0002) and (b) waist
circumference (P = 003). Lean, BMI
< 25 kg m2; overweight, BMI 25–
30 kg m2; obese, BMI > 30 kg m2; PASI,
Psoriasis Area and Severity Index.
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